Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Incannex Healthcare Inc. (NASDAQ:IXHL), a cannabinoid and psychedelic medicine biotechnology company, announced Tuesday a significant financing agreement with Arena Investors, securing up to $60 million in funding. The deal includes $10 million in convertible notes and a $50 million equity line of credit (ELOC) with Arena Business Solutions (ABS), a related entity.
大麻素和迷幻藥物生物技術公司Incannex Healthcare Inc.（納斯達克股票代碼：IXHL）週二宣佈與Arena Investors達成一項重大融資協議，獲得高達6000萬美元的融資。該交易包括1000萬美元的可轉換票據和與關聯實體Arena Business Solutions（ABS）的5000萬美元股票信貸額度（ELOC）。
The financing will support the advancement of Incannex's clinical trials for its proprietary, synthetic cannabinoid and psychedelic-assisted therapeutics, targeting chronic conditions.
這筆資金將支持Incannex針對慢性病的專有合成大麻素和迷幻輔助療法的臨床試驗的進展。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 每天在收件箱中免費獲取Benzinga的獨家分析以及有關大麻行業和市場的熱門新聞。在這裏訂閱我們的時事通訊。如果你認真對待這項業務，就不能錯過這個機會。
Key Trials Progressing, Says Incannex CEO
Incannex 首席執行官表示，關鍵試驗正在進行中
Joel Latham, president and CEO of Incannex, expressed optimism about the partnership, highlighting its potential to drive key late-stage clinical milestones. "We look forward to updating investors on our progress, including progressing IHL-42X through Phase 2/3 trials for the treatment of obstructive sleep apnea, PsiGAD through a Phase 2 study for generalized anxiety disorder and IHL-675A through a Phase 2 trial for rheumatoid arthritis," Latham stated in a press release.
Incannex總裁兼首席執行官喬爾·萊瑟姆對該合作伙伴關係表示樂觀，強調其有可能推動關鍵的後期臨床里程碑。萊瑟姆在一份新聞稿中表示：「我們期待向投資者通報我們的最新進展，包括將 IHL-42X 推進治療阻塞性睡眠呼吸暫停的2/3期試驗，將psIGad推進廣泛性焦慮症的2期研究，將 IHL-675A 推進類風溼關節炎的2期試驗。」
Read Also: Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects
另請閱讀：Psilera的psilocybin藥物可以在沒有精神活性作用的情況下治療額膜癡呆
Incannex Financing Aligned With Strategic Goals
Incannex 融資與戰略目標一致
Upon closing, Incannex will receive an initial tranche of $3.33 million, with the option to access two additional tranches totaling $6.67 million. The $50 million ELOC allows the company to issue and sell shares over the next 36 months, providing flexible capital as needed.
交易完成後，Incannex將獲得333萬澳元的首批資金，並可選擇獲得另外兩筆總額爲667萬美元的資金。5000萬美元的ELOC允許公司在未來36個月內發行和出售股票，並根據需要提供靈活的資本。
Furthermore, Incannex plans to use the funds to support clinical trials and general corporate purposes, with allocations aligned with the company's strategic priorities.
此外，Incannex計劃將這筆資金用於支持臨床試驗和一般公司用途，其撥款與公司的戰略優先事項保持一致。
IXHL Price Actio
IXHL's shares were trading 0.62% lower at $1.60 per share at the time of this writing around 11:45 AM ET Tuesday.
IXHL 價格走勢
在撰寫本文時，美國東部時間週二上午11點45分左右，IXHL的股價下跌0.62％，至每股1.60美元。
Related News
相關新聞
- Moxy: The Short, Intense Psychedelic High Sweeping The Globe
- Moxy：席捲全球的短暫而激烈的迷幻高潮
Photo: Courtesy of Hvoenok and GOR Photo on Shutterstock.
照片：由 Shutterstock 上的 Hvoenok 和 GOR Photo 提供。
譯文內容由第三人軟體翻譯。
